<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442492</url>
  </required_header>
  <id_info>
    <org_study_id>H15-00899</org_study_id>
    <nct_id>NCT02442492</nct_id>
  </id_info>
  <brief_title>Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction</brief_title>
  <acronym>STRIDER Canada</acronym>
  <official_title>STRIDER Canada: A Randomized Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (Canada)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early-onset placental intrauterine growth restriction (EO IUGR) is associated with a high
      risk of perinatal morbidity and mortality. In association with reduced circulating placental
      growth factor (PlGF) EO IUGR results from abnormal placentation with inadequate remodelling
      of the maternal uteroplacental arteries. There is no known treatment for placental IUGR.
      Management involves intensive fetal surveillance with delivery with evidence of serious fetal
      compromise. However, remote from term, delivery is associated with significant perinatal
      mortality and morbidity. Sildenafil vasodilates the uteroplacental vessels of IUGR-affected
      pregnancies and may represent a novel therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STRIDER Canada is one of a consortium of STRIDER randomised controlled trials (RCTs) each of
      which is designed to determine whether or not maternal treatment with oral sildenafil citrate
      improves perinatal outcomes in pregnancies complicated by EO IUGR without increasing risks to
      the mother.

      STRIDER Canada is designed as investigator-initiated double-blind, randomised
      placebo-controlled trial of 90 women with a diagnosis of early-onset intrauterine growth
      restriction with an intention-to-treat analysis. 90 Women with affected pregnancies will be
      recruited and randomised to receive either sildenafil or placebo.

      Women reviewed in the participating fetal medicine with a diagnosis of a pregnancy affected
      by early-onset IUGR between 18+0 and 27+6 weeks of gestation and serum PlGF levels less than
      5th percentile for gestational age will be considered for randomisation. In Canadian STRIDER,
      the treatment with either sildenafil or placebo (25 mg 3 times per day) will be applied from
      the time of randomisation until delivery, or up to 31+6 weeks of gestation whichever comes
      first.

      All patients randomly assigned to one of the treatments will be analysed together, regardless
      of whether or not they completed or received that treatment, on an intention to treat basis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare the gestational age at delivery (d) between sildenafil- and placebo-treated groups</measure>
    <time_frame>6 weeks after postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>live birth</measure>
    <time_frame>at delivery if alive</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival to hospital discharge</measure>
    <time_frame>measured at the final hospital discharge (average upto 6 weeks postpartum)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intact survival (defined as survival to estimated due date (EDD) without evidence of severe central nervous system [CNS] injury [by ultrasound and/or magnetic resonance imaging (MRI)])</measure>
    <time_frame>measured at estimated due date (EDD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite non-CNS (Central Nervous System) severe morbidity (one/more of bronchopulmonary dysplasia requiring supplemental oxygen on hospital discharge, â‰¥grade 3 retinopathy of prematurity, or necrotising enterocolitis)</measure>
    <time_frame>up to 6 weeks after postpartum or final discharge which ever is sooner</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Maternal - symptomatic hypotension</measure>
    <time_frame>up to 6 weeks after postpartum or final discharge which ever is sooner</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal - pre-eclampsia</measure>
    <time_frame>from randomisation to delivery (expected to be assessed weekly)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal - mode of delivery</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal - haemorrhage requiring transfusion</measure>
    <time_frame>At delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal - maternal plasma PlGF.</measure>
    <time_frame>from randomisation to delivery (expected to be assessed weekly)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal - uterine artery Doppler indices</measure>
    <time_frame>from randomisation to delivery (expected to be done weekly)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Perinatal - fetal growth velocity</measure>
    <time_frame>from randomisation to delivery (expected to be done weekly)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Perinatal - fetal Doppler</measure>
    <time_frame>from randomisation to delivery (expected to be done weekly)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Perinatal - amniotic fluid</measure>
    <time_frame>At randomisation, if done</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Perinatal - fetal heart indices</measure>
    <time_frame>rom randomisation to delivery (expected to be done weekly)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Intrauterine Growth Restriction (IUGR)</condition>
  <condition>Fetal Growth Restriction (FGR)</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.</description>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age from 18+0 - 27+6 weeks

        AND

          -  EO IUGR, defined as

               1. ultrasound (U/S) measurement of the fetal abdominal circumference (AC) &lt;10th
                  percentile for gestational age and/or documented reduced fetal growth velocity
                  complicating either a prior EO IUGR with adverse perinatal outcome or abnormal
                  uterine artery waveform in the index pregnancy;

                  OR

               2. U/S estimate of fetal weight (EFW) &lt;700g

        AND

          -  Serum PlGF &lt; 5th percentile for gestational age

        Exclusion Criteria:

          -  known fetal aneuploidy

          -  known fetal anomaly/syndrome/congenital infection confirmed at the time of enrolment

          -  decision made to terminate pregnancy

          -  current cocaine or vasoconstrictor use (e.g. crystal meth) (risk of acute cardiac
             events)

          -  contraindication to sildenafil therapy, e.g. known significant maternal cardiac
             disease, left ventricular outflow tract obstruction, concomitant treatment with
             nitrates or previous allergy to sildenafil

          -  known HIV positive status (due drug-drug interaction between sildenafil and
             antiretrovirals)

          -  receiving peripheral alpha-blockers (e.g. prazosin)

          -  prior participation in a STRIDER trials

          -  pre-eclampsia or gestational hypertension diagnosed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter von Dadelszen, BMedSc, MBChB, DipObst, DPhil,</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Lim, MD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youkee Chung</last_name>
    <phone>604-875-2424</phone>
    <phone_ext>4662</phone_ext>
    <email>STRIDERCanada@cw.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chirag Kariya</last_name>
    <phone>604-875-2424</phone>
    <phone_ext>4889</phone_ext>
    <email>chirag.kariya@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BC Women's Hospital/University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V7H3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youkee Chung, BSc</last_name>
      <phone>604 875 2424</phone>
      <phone_ext>4662</phone_ext>
      <email>STRIDERCanada@cw.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kenneth I Lim, MD</last_name>
      <phone>604 875 2665</phone>
      <email>klim@cw.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth I Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasna Meddour, CCRP</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>7169</phone_ext>
      <email>hasna.meddour@recherche-ste-justine.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Gloria Sanchez, BSc</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>7580</phone_ext>
      <email>gloria.sanchez@recherche-ste-justine.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Francois Audibert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Universite Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G2N 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Tapp, MSc</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>46039</phone_ext>
      <email>Sylvie.Tapp@crchudequebec.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Genevieve Laforest, MSc</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>46306</phone_ext>
      <email>Genevieve.Laforest@crchudequebec.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel Bujold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Kenneth Lim</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sildenafil</keyword>
  <keyword>IUGR</keyword>
  <keyword>FGR</keyword>
  <keyword>STRIDER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

